Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics

Breast cancer pathobiology is known to be influenced by the differential expression of a group of proteins called the kinesin superfamily (KIFs), which is instrumental in the intracellular transport of chromosomes along microtubules during mitosis. During cellular division, kinesins are strictly reg...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene 2018-02, Vol.37 (7), p.833-838
Main Authors: Lucanus, A J, Yip, G W
Format: Article
Language:English
Subjects:
631/67/1347
692/53/2422
Animals
Antineoplastic Agents - therapeutic use
Apoptosis
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Care and treatment
Cell Biology
Chromosomes
Female
Genetic aspects
Health risk assessment
Human Genetics
Humans
Internal Medicine
Kinesin
Kinesin - antagonists & inhibitors
Kinesin - metabolism
Medical prognosis
Medicine
Medicine & Public Health
Microtubules
Microtubules - metabolism
Mitosis
Multigene Family
Oncology
Prognosis
Proteins
review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer pathobiology is known to be influenced by the differential expression of a group of proteins called the kinesin superfamily (KIFs), which is instrumental in the intracellular transport of chromosomes along microtubules during mitosis. During cellular division, kinesins are strictly regulated through temporal synthesis so that they are present only when needed. However, their misregulation may contribute to uncontrolled cell growth owing to premature sister chromatid separation, highlighting their importance in cancer. This review covers the functions of kinesins in normal and breast cancer cells, the use of kinesins for breast cancer patient prognosis, and the targeting of these molecules for therapeutics. A better understanding of KIF proteins may be pivotal to improved disease outcomes for breast cancer patients.
ISSN:0950-9232
1476-5594
DOI:10.1038/onc.2017.406